Dr. Carol Prives has been elected as a Fellow of the Royal Society. According to Venki Ramakrishnan, President of the Royal Society, “At this time of global crisis, the importance of scientific thinking, and the medicines, technologies and insights it delivers, has never been clearer. Our Fellows and Foreign Members are central to the mission of the Royal Society, to use science for the benefit of humanity.”
Dr. Prives has been recognized for her work on elucidating the functions of p53, a major tumor suppressor protein whose gene is the most frequently mutated in human cancer. She has identified key activities and properties of both the normal, wild-type form of the protein and the cancer-related mutant versions of this protein. Her work has provided insight into how wild-type p53 protects cells from becoming cancerous and how mutant forms of p53 promote the malignant behavior of cancer cells. In addition to receiving numerous awards, Dr. Prives has previously been recognized by election to the American Academy of Arts and Sciences, the National Academy of Medicine, the AACR Academy and the National Academy of Science.